THE INFLUENCE OF CYP2C8*3 ON CARBAMAZEPINE SERUM CONCENTRATION IN EPILEPTIC PEDIATRIC PATIENTS

Milovanovic DD1, Milovanovic JR1, Radovanovic M2, Radosavljevic I1, Obradovic S2, Jankovic S1, Milovanovic D1, Djordjevic N1

*Corresponding Author: Natasa Djordjevic, M.D., Ph.D., Associate Professor, Department of Pharmacology and Toxicology, Faculty of Medical Sciences, University of Kragujevac, Svetozara Markovica 69, 34 000 Kragujevac, Serbia. Tel: +381-34-306-800, ext 223. Fax: +381-34-306-800. E-mail: natashadj2002@yahoo.com

ABSTRACT

The aim of the present study was to investigate the distribution of CYP2C8 variants *3 and *5, as well as their effect on carbamazepine pharmacokinetic properties, in 40 epileptic pediatric patients on carbamazepine treatment. Genotyping was conducted using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), and allele-specific (AS)-PCR methods, and steady-state carbamazepine plasma concentrations were determined by high performance liquid chromatography (HPLC). The CYP2C8 *3 and *5 polymorphisms were found at frequencies of 17.5 and 0.0%, respectively. After dose adjustment, there was a difference in daily dose in CYP2C8*3 carriers compared to non carriers [mean ± standard deviation (SD): 14.19 ± 5.39 vs. 15.46 ± 4.35 mg/kg; p = 0.5]. Dose-normalized serum concentration of carbamazepine was higher in CYP2C8*3 carriers than in non carriers [mean ± SD: 0.54 ± 0.18 vs. 0.43 ± 0.11 mg/mL, p = 0.04], and the observed correlation between weight-adjusted carbamazepine dose and carbamazepine concentration after dose adjustment was significant only in CYP2C8*3 non carriers (r = 0.52, p = 0.002). However, the population pharmacokinetic analysis failed to demonstrate any significant effect of CYP2C8 *3 polymorphism on carbamazepine clearance [CL L/h = 0.215 + 0.0696*SEX+ 0.000183*DD]. The results indicated that the CYP2C8*3 polymorphism might not be of clinical importance for epilepsy treatment in pediatric populations.

Keywords: Carbamazepine pharmacokinetics; Children; CYP2C8*3; Population pharmacokinetics.

INTRODUCTION

Carbamazepine belongs to the older generation of anticonvulsants, which is almost completely metabolized in the liver through processes that involve several liver enzymes, including CYP2C8 [1-4]. To date, there are 16 different CYP2C8 alleles described (http://www.cypalleles.ki.se/cyp2c8.htm), most of them associated with altered enzyme activity [5]. Although genes could affect the drug metabolism there is a general lack of evidence of influence of CYP2C8 genetic variations on carbamazepine pharmacokinetics, especially in children [6]. Since the drug metabolism in the pediatric population is specific [7], the extrapolation of knowledge from adults, without prior evidence of how various factors influence drug metabolism, may lead to improper management of pediatric therapy [8]. Therefore, the main aim of this study was to investigate the effect of the CYP2C8 genetic polymorphisms on carbamazepine dosing, serum concentration and clearance, in epileptic pediatric patients.
MATERIALS AND METHODS

The study was conducted at the Clinical Centre, Kragujevac, Serbia, and involved 40 epileptic pediatric patients on ongoing therapy with carbamazepine [9]. Except for four patients, who were on comedication with valproate, all others were on monotherapy. The study was approved by the relevant Ethics Committee (approval No. 01-7848) and conducted in accordance with the Declaration of Helsinki and its subsequent revisions.

Blood samples for drug concentration analysis were collected twice, both times at the minimal concentration point (8-12 hours after the administration of the last dose): at the beginning of the study, and 4 weeks after dose adjustment. The steady-state carbamazepine serum concentrations were determined by validated high pressure liquid chromatography (HPLC) assay, as described by Jankovic et al. [10]. An additional blood sample was taken for CYP2C8 genotyping, and DNA was isolated using the PurelinkTM genomic DNA kit (Invitrogen, Carlsbad, CA, USA). CYP2C8*3 (416G>A, rs11572080) and CYP2C8*5 (475delA, rs72558196) were genotyped using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and allele-specific (AS)-PCR methods, respectively, according to Nakajima et al. [11]. Primers and restriction enzyme were from Invitrogen and New England Biolabs (Ipswich, MA, USA), respectively, while all other reagents used were made by Thermo Scientific (Waltham, MA, USA) or Qiagen GmbH (Hilden, Germany). Electrophoresis on a 1.2% agarose gel, stained with Sybr® safe DNA gel stain (Invitrogen), was used to detect the obtained PCR products and restriction fragments.

To determine the factors affecting carbamazepine clearance, population pharmacokinetic modeling was employed, using the nonlinear mixed effect model (NONMEM) software, version 7.3.0 (Icon Development Solution, Hanover, MD, USA), and ADVAN 1 subroutine (within NONMEM) (one compartment model with no absorption). Carbamazepine serum concentrations, age, body weight, sex, total carbamazepine daily dose, CYP2C8 genotype and concomitant therapy with valproate, were included as covariates by the stepwise addition process in the model construction, and their significance was estimated by the likelihood ratio test. The final model was built through a backward deletion from the full model, using covariates that met criteria of the minimum objective function value difference of more than 6.6 for nominal \( p < 0.01 \) and degree of freedom (df) = 1. Inter-patient variability of the clearance and intrapatient (residual) variability in the concentration was estimated by exponential, additive, or proportional error model. Data distribution was assessed through the ratio of predicted (PRED) and measured the dependent variable (DV) concentrations of the drug, as well as the ratio in the weighted residuals (WRES) and PRED values of carbamazepine from the base to the final model. Bootstrapping analysis, as a preferable validation procedure for the small study sample size, was used to evaluate the predictive performance of the final model.

Statistical Analyses. The haplotype analysis was done by the population genetic software program Arlequin, version 3.11 (http://cmpg.unibe.ch/software/arlequin3), and Statistica, version 7.1 (StatSoft, Tulsa, OK, USA) was used for all other statistical analyses. The observed and expected allele frequencies were compared by the \( \chi^2 \) test, and consistency of the data with the normal distribution was assessed by the Shapiro-Wilk test. The Spearman analysis was used to correlate doses and concentrations of carbamazepine, and the Student \( t \)-test for independent groups was used for assessment of dose requirements and carbamazepine serum concentrations in the CYP2C8*3 carrier and non carrier groups. A \( p \) value of <0.05 was considered significant.

RESULTS

The assessment included 24 male and 16 female pediatric patients, aged 4-16 years (median: 11 years), weighing 17 to 65 kg (median: 39 kg). All patients received daily doses of 260 to 1000 mg orally as tablets or syrup, and four of them were on concomitant therapy with valproate. Observed CYP2C8 genotype frequencies (Table 1) were in accordance with the Hardy-Weinberg equilibrium (\( \chi^2 <1.111, p = 0.05 \)). As there was only one carrier of the CYP2C8*3/*3 genotype (no CYP2C8*5 was observed), all subjects were designated as either CYP2C8*3 carriers (CYP2C8*1A/*3 or CYP2C8*3/*3) or CYP2C8*3 non carriers (CYP2C8*1A/*1A). After dose adjustment based on the serum concentration, the daily carbamazepine dose was
found to be lower in CYP2C8*3 carriers compared to CYP2C8*3 non-carriers, although the difference was not statistically significant [mean ± SD (standard deviation): 14.19 ± 5.39 mg/kg vs. 15.46 ± 4.35 mg/kg, \( p = 0.5 \)]. The observed dose and \( p \) values remained exactly the same when valproate users were excluded from comparison. At the same time, higher dose-normalized serum concentration of carbamazepine was observed in CYP2C8*3 carriers compared to CYP2C8*3 non-carriers (mean ± SD: 0.54 ± 0.18 vs. 0.43 ± 0.11 mg/mL, \( p = 0.04 \)) (Figure 1). The observed correlation between weight-adjusted carbamazepine dose and carbamazepine concentration after dose adjustment was significant only in CYP2C8*3 non-carriers (\( r = 0.52, p = 0.002 \)) (Figure 2).

The mean population value for carbamazepine clearance, estimated by the base population pharmacokinetics model, was 4.04 L/h. Inter- and intra-patient variability was best described by exponential model error, with the values of 41.37 and 22.64%, respectively. Out of six examined factors, only three met the minimum objective function value (MOF) difference requirement, and thus, were included in the full model: the total carbamazepine daily dose, sex and concomitant therapy with valproate. The process of backward deletion of covariates from the full model resulted in the following equation:

\[
CL (L/h) = 0.215 + 0.0696 \times SEX + 0.000183 \times DD,
\]

where SEX has a value of 1 if male and 0 if female, and DD is the total carbamazepine daily dose (mg/day). Value of MOF in the final model was

---

**Table 1. Nucleotide change, haplotype and genotype frequencies of CYP2C8 in Serbian epileptic pediatric patients on carbamazepine treatment.**

| Nucleotide change: | Observed Frequency | 95% CI       |
|--------------------|-------------------|--------------|
| 416G>A             | 0.100 (8/80)      | 0.050, 0.188 |
| 475delA            | 0.000 (0/80)      | 0.000, 0.056 |

| Haplotype:         | Observed Frequency | 95% CI       |
|--------------------|-------------------|--------------|
| CYP2C8*1A/CYP2C8*3 | 0.900 (72/80)     | 0.812, 0.950 |
| CYP2C8*1A/CYP2C8*5 | 0.100 (8/80)      | 0.050, 0.188 |
| CYP2C8*3/CYP2C8*5  | 0.000 (0/80)      | 0.000, 0.056 |

| Genotype:          | Observed Frequency | 95% CI       |
|--------------------|-------------------|--------------|
| CYP2C8*1A/CYP2C8*1A| 0.825 (33/40)     | 0.676, 0.861 |
| CYP2C8*1A/CYP2C8*3 | 0.150 (6/40)      | 0.068, 0.245 |
| CYP2C8*3/CYP2C8*3  | 0.025 (1/40)      | 0.000, 0.109 |

95% CI: 95% confidence interval.
Table 2. The final model parameter estimates.

| Parameters                  | NONMEM  | Bootstrap Analysis |
|-----------------------------|---------|--------------------|
|                             | Estimate| 95% CI             | Estimate| 95% CI       |
| Clearance (L/h)             | 0.215   | 0.176-0.254        | 0.207   | 0.189-0.225  |
| Sex                         | 0.0696  | 0.0545-0.0847      | 0.0698  | 0.0527-0.869 |
| Daily dose of carbamazepine (mg/L) | 0.000183 | 0.000079-0.000287 | 0.000194 | 0.000141-0.000247 |
| Inter-individual variance of CL | 0.0626 | 0.0371-0.0881     | 0.0669  | 0.058-0.0758 |
| Residual variance (exponential) | 0.0249 | 0.018-0.318       | 0.0262  | 0.023-0.0294 |

NONMEM: nonlinear mixed effect model.

a Estimate ± 1.96 × (standard error of the estimate).

b Percentile (2.5 and 97.5) of the ranked bootstrap parameter estimates.

148.759 units lower compared to the base model. The final model parameter estimates are presented in Table 2. Both inter- and intra-patient variability were decreased by 25.42 and 15.88%, respectively. The bootstrapping analysis that was conducted on 200 replicated data with replacement, resulted in similar values of carbamazepine clearance, effects of total carbamazepine daily dose, sex, and inter- and intra-patients variability, indicating a good precision and stability of the final model.

**DISCUSSION**

The present study investigated the distribution frequency of *CYP2C8* variations *3* (g.416G>A) and *5* (g.475delA), and their influence on carbamazepine dosing, serum concentration and clearance, in Serbian epileptic pediatric patients. Additionally, we estimated the effect of standard covariates such as body weight, age, sex, total daily dose of carbamazepine and other anticonvulsants on carbamazepine clearance. The results rendered sex and total carbamazepine daily dose relevant for carbamazepine treatment. The *CYP2C8* genetic polymorphism significantly affects carbamazepine metabolism, but its role seems not to be clinically important.

*CYP2C8* is a phase I metabolizing enzyme involved in biotransformation of numerous drugs [12,13]. Although not the major role player in carbamazepine pharmacokinetics, it is considered to be of importance as it promotes conversion of the drug to its active metabolite carbamazepine-10,11-epoxide [14]. In addition, the *CYP2C8* enzyme is inducible, with the induction mediated, among others, by pregnane X and the constitutive androstane receptor [15]. As both of these receptors might be activated by carbamazepine [16,17], it could be speculated that the contribution of *CYP2C8* in carbamazepine metabolism is more complicated compared to its other substrates. Therefore, the polymorphism of the *CYP2C8* coding gene could partly explain observed inter-individual variation in response to carbamazepine treatment [18]. In Caucasians, *CYP2C8* *3* (g.416G>A) is the most common nonsynonymous variant, frequently associated with decreased enzyme activity [12]. On the other hand, *CYP2C8* *5* (g.475delA) belongs to rare variations, but raises attention as one of the few that yield highly truncated and most probably completely inactive enzyme [19]. Based on the present study, the frequencies of *CYP2C8* *3* and *CYP2C8* *5* polymorphisms in the Serbian population are in accordance with the data obtained from other Caucasian populations [5,20-22].

Effects of the *CYP2C8* polymorphism on drug metabolism have already been investigated [6,21-26]. Although the activity of the most frequent *CYP2C8* variant *3* appears to be substrate-dependent [6], its influence on carbamazepine pharmacokinetics was not explored. In the present study, there was a tendency toward lower daily dose and higher serum concentrations of carbamazepine in *CYP2C8* *3* carriers, indicating decreased enzyme activity and slower metabolism of the drug. In addition, the observed correlation between carbamazepine dose and concentration was found to be significant only in carriers of the *CYP2C8* wild type allele. The lack of similar correlation in the presence of the *3* variant suggests the existence of other factors that might affect carbamazepine pharmacokinetics, e.g., by altering the binding activity of the variant *CYP2C8* enzyme [27]. Another plausible explanations might include the possible dose-dependent autoinduction of...
carbamazepine CYP2C8-mediated metabolism [28], and/or the linkage disequilibrium between *3 and other CYP2C8 alleles [18]. Regardless of the cause, the presented findings render CYP2C8*3 carriers especially susceptible to an unpredictable reaction to carbamazepine, and therefore, good candidates for a closer follow-up during treatment, especially as the drug concentration in these patients proved not to be sufficient to guide the dose adjustment.

To further test whether CYP2C8*3 genotyping should be considered as a routine analysis in patients on carbamazepine, population pharmacokinetic analysis was performed. Numerous pharmacokinetic models are already available from the literature dealing with carbamazepine clearance [29-32]. Bearing in mind that carbamazepine is the most frequently used anticonvulsant in Serbia [10], we considered it relevant to evaluate the CYP2C8 genetic polymorphism in a pharmacokinetic model in Serbian epileptic pediatric patients. Population pharmacokinetic analysis, which included CYP2C8*3 genotype as a covariate, failed to demonstrate a significant effect of genetic polymorphism on carbamazepine clearance. Unlike some other drug therapies investigated so far [21,22,24], our study showed that CYP2C8 might be of lesser clinical importance to carbamazepine treatment. Yet, the rather small sample size limited the generality of our findings, and additional studies, involving more subjects and also other populations, would be required for a better understanding of CYP2C8 polymorphism effects on epileptic patients’ reaction to carbamazepine.

Other findings of our population pharmacokinetic analysis included sex and total carbamazepine daily dose as significant indicators of carbamazepine clearance. The observed effect of sex has been previously reported, with girls having lower values for clearance, most probably due to estrogen influence on microsomal enzymes activity [28,33,34]. However, most of the authors did not show such differences, thus the predictive value of sex for carbamazepine clearance remains controversial [10,30,35-38]. On the contrary, most of the studies denoted positive correlation of carbamazepine daily dose with the drug clearance [32,39,40], and our results confirm those reports.

In conclusion, our results do not support routine genotyping of CYP2C8 in Serbian epileptic pediatric patients on carbamazepine treatment. Yet, significantly higher serum concentrations in CYP2C8*3 carriers confirm the importance of CYP2C8 genetic polymorphism for carbamazepine pharmacokinetics, warranting further investigations.

Declaration of Interest. This study was supported by the Faculty of Medical Sciences, University of Kragujevac, Serbia, JP 07/11, and the Ministry of Science and Technology of the Republic of Serbia, grants No. 175007 and 175056. The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.

REFERENCES

1. Brunton LL, Lazo JS, Parker KL, Eds. Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 11th ed. New York, NY, USA: The McGraw-Hill Companies Inc., 2006.
2. Ritter JM, Lewis LD, Mant TG, Ferro A, Eds. A Textbook of Clinical Pharmacology and Therapeutics, 5th ed. London, UK: Hodder Arnold, an imprint of Hoddon Education, part of Hachette Livre UK, 2008.
3. Wells BG, Dipiro JT, Schwinghammer TL, Dipiro CV, Eds. Pharmacotherapy Handbook, 7th ed. New York, NY, USA: The McGraw-Hill Companies, Inc., 2009.
4. Tomalik-Scharte D, Fuhr U, Hellmich M, Frank D, Doroshynenko O, et al. Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide. Drug Metab Disposition. 2011; 39(5): 927-932.
5. Pechandova K, Buzkova H, Matouskova O, Perlik F, Slanar O. Genetic polymorphisms of CYP2C8 in the Czech Republic. Genet Test Mol Biomarkers. 2012; 16(7): 812-816.
6. Aquilante CL, Bushman LR, Knutsen SD, Burt LE, Rome LC, Kosmiski LA. Influence of SLC01B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers. Hum Genomics. 2008; 3(1): 7-16.
7. Yokoi T. Essentials for starting a pediatric clinical study (1): Pharmacokinetics in children. J Toxicol Sci. 2009; 34(2): 307-312.
8. Cella M, Knibbe C, Danhof M, Pasqua OD. What is the right dose for children. Br J Clin Pharmacol. 2010; 70(4): 597-603.
9. Djordjevic N, Milovanovic DD, Radovanovic M, Radosavljevic I, Obradovic S, Jakovljevic M,
et al. CYP1 A2 genotype affects carbamazepine pharmacokinetics in children with epilepsy. Eur J Clin Pharmacol. 2016; 72(4): 439-445.

10. Jankovic SM, Jovanovic D, Milovanovic JR. Pharmacokinetic modeling of carbamazepine based on clinical data from Serbian epileptic patients. Methods Find Exp Clin Pharmacol. 2008; 30(9): 707-713.

11. Nakajima M, Fujiki Y, Noda K, Ohtsuka H, Okuni H, Kyo S, et al. Genetic polymorphism of CYP2C8 in Japanese population. Drug Metab Dispos. 2003; 31(6): 687-690.

12. Aquilante CL, Niemi M, Gong L, Altman RB, Klein TE. PharmGKB summary: Very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8. Pharmacogenet Genomics. 2013; 23(12): 721-728.

13. Hichiya H, Tanaka-Kagawa T, Soyama A, Jinno H, Koyano S, Katori N, et al. Functional characterization of five novel CYP2C8 variants, G171S, R186X, R186G, K247R, and K383N, found in a Japanese population. Drug Metab Dispos. 2005; 33(5): 630-636.

14. Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012; 92(4): 414-417.

15. Fergusson SS, Chen Y, LeCluyse EL, Goldstein JA. Human CYP2C8 is transcriptionally regulated by the nuclear receptors constitutive androstane receptor, pregnane X receptor, glucocorticoid receptor, and hepatic nuclear factor 4alpha. Mol Pharmacol. 2005; 68(3): 747-757.

16. Oscarson M, Zanger UM, Rifkin OF, Klein K, Eichelbaum M, Meyer UA. Transcriptional profiling of genes induced in the livers of patients treated with car-bamazepine. Clin Pharmacol Ther. 2006; 80(5): 440-456.

17. Owen A, Goldring C, Morgan P, Park BK, Pirmohamed M. Induction of P-glycoprotein in lymphocytes by carbamazepine and rifampicin: The role of nuclear hormone response elements. Br J Clin Pharmacol. 2006; 62(2): 237-242.

18. Thorn CF, Leckband SG, Kelsoe J, Leeder JS, Muller DJ, Klein TE, et al. PharmGKB summary: Car-bamazepine pathway. Pharmacogenet Genomics. 2011; 21(12): 906-910.

19. Soyama A, Saito Y, Momamura K, Ueno K, Kamakura S, Ozawa S, et al. Five novel single nucleotide polymorphisms in the CYP2C8 gene, one of which induces a frame-shift. Drug Metabol Pharmacokin. 2002; 17(4): 374-377.

20. Bahadur N, Leathart JB, Mutch E, Steimel-Crespi D, Dunn SA, Gilissen R, et al. CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes. Biochem Pharmacol. 2002; 64(11): 1579-1589.

21. Niemi M, Leathart JB, Neuvonen M, Backman JT, Daly AK, Neuvonen PJ. Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. Clin Pharmacol Ther. 2003; 74(4): 380-387.

22. Martinez C, Garcia-Martín E, Blanco G, Gamito FJG, Ladero JM, Agündez JAG. The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects. Br J Clin Pharmacol. 2004; 59(1): 62-68.

23. Kircheiner J, Thomas S, Bauer S, Tomalik-Scharte D, Hering U, Doroshynenko O, et al. Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype. Clin Pharmacol Ther. 2006; 80(6): 657-667.

24. Bergmann TK, Brasch-Andersen C, Green H, Mirza M, Pedersen RS, Nielsen F, et al. Impact of CYP2C8 *3 on paclitaxel clearance: A population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. Pharmacogenomics J. 2011; 11(2): 113-120.

25. Wójcikowski J, Basińska A, Daniel WA. The cytochrome P450-catalyzed metabolism of levomepromazine: A phenothiazine neuroleptic with a wide spectrum of clinical application. Biochem Pharmacol. 2014; 90(2): 188-195.

26. Daily EB, Aquilante CL. Cytochrome P450 2C8 pharmacogenetics: A review of clinical studies. Pharmacogenomics. 2009; 10(9): 1489-1510.

27. Kaspera R, Naraharisetti SB, Evangelista EA, Marcianite KD, Psaty BM, Totah RA. Drug metabolism by CYP2C8.3 is determined by substrate dependent interactions with cytochrome P450 reductase and cytochrome b5. Biochem Pharmacol. 2011; 82(6): 681-691.
28. Liu H, Delgado MR. Influence of sex, age, weight, and carbamazepine dose on serum concentrations, concentration ratios, and level/dose ratios of carbamazepine and its metabolites. Ther Drug Monit. 1994; 16(5): 469-476.

29. Gray AL, Botha JH, Miller R. A model for the determination of carbamazepine clearance in children on mono- and polytherapy. Eur J Clin Pharmacol. 1998; 54(4): 359-362.

30. Chan E, Lee HS, Hue SS. Population pharmacokinetics of carbamazepine in Singapore epileptic patients. Br J Clin Pharmacol. 2001; 51(6): 567-576.

31. Deleu D, Aarons L, Ahmed I. Population pharmacokinetics of free carbamazepine in adult Omani epileptic patients. Eur J Clin Pharmacol. 2001; 57(3): 243-248.

32. Jiao Z, Shi XJ, Zhao ZG, Zhong MK. Population pharmacokinetic modeling of steady state clearance of carbamazepine and its epoxide metabolite from sparse routine clinical data. J Clin Pharm Ther. 2004; 29(3): 247-256.

33. Furlanut M, Montanari G, Bonin P, Casara GL. Carbamazepine and carbamazepine-10,11-epoxide serum concentrations in epileptic children. J Pediatr. 1985; 106(3): 491-495.

34. Summers B, Summers RS. Carbamazepine clearance in pediatric epilepsy patients. Influence of both mass, dose, sex and co-medication. Clin Pharmacokinet. 1989; 17(3): 208-216.

35. Reith DM, Hooper WD, Parke J, Charles B. Population pharmacokinetic modeling of steady state carbamazepine clearance in children, adolescents, and adults. J Pharmacokinet Pharmacodyn. 2001; 28(1): 79-92.

36. El Desoky ES, Sabarinath SN, Hamdi MM, Bewernitz M, Derendorf H. Population pharmacokinetics of steady-state carbamazepine in Egyptian epilepsy patients. J Clin Pharm Ther. 2012; 37(3): 352-355.

37. Wang Y, Zhang HN, Niu CH, Gao P, Chen YJ, Peng J, et al. Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. Acta Pharmacol Sin. 2014; 35(10): 1342-1350.

38. Milovanovic JR, Jankovic SM. Factors influencing carbamazepine pharmacokinetics in children and adults: Population pharmacokinetic analysis. Int J Clin Pharmacol Ther. 2011; 49(7): 428-436.

39. Delgado Iribarnegaray MF, Santo Bueldga D, García Sánchez MJ, Otero MJ, Falcão AC, Domínguez-Gil A. Carbamazepine population pharmacokinetics in children: Mixed-effect models. Ther Drug Monit. 1997; 19(2): 132-139.

40. Jiao Z, Zhong MK, Shi XJ, Hu M, Zhang JH. Population pharmacokinetics of carbamazepine in Chinese epilepsy patients. Ther Drug Monit. 2003; 25(3): 279-286.
